Histogen Inc
OTC:HSTO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Histogen Inc
OTC:HSTO
|
US |
Histogen Inc
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing its hypoxia-generated growth factor technology platform and stem cell-free biologic products as restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The firm's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. In addition, within its small molecule pipeline, its product candidates also include CTS-2090 and CTS-2096. Its HST-003 is a human extracellular matrix (hECM), which is focused on regenerating hyaline cartilage for the treatment of articular cartilage defects in the knee, with a malleable scaffold that stimulates the body’s own stem cells. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being developed for the treatment of COVID-19.
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing its hypoxia-generated growth factor technology platform and stem cell-free biologic products as restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The firm's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. In addition, within its small molecule pipeline, its product candidates also include CTS-2090 and CTS-2096. Its HST-003 is a human extracellular matrix (hECM), which is focused on regenerating hyaline cartilage for the treatment of articular cartilage defects in the knee, with a malleable scaffold that stimulates the body’s own stem cells. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being developed for the treatment of COVID-19.
